Stockreport

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics, Inc.  (CADL) 
PDF Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, [Read more]